title: Accuracy of marker analysis, quantitative real-time polymerase chain reaction, and multiple ligation-dependent probe amplification to determine SMN2 copy number in patients with spinal muscular atrophy.
abstract: Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder caused by absence of or mutations in the survival motor neuron1 gene (SMN1). All SMA patients have a highly homologous copy of SMN1, the SMN2 gene. Severe (type I) SMA patients present one or two SMN2 copies, whereas milder chronic forms (type II-III) usually have three or four SMN2 copies. SMN2 dosage is important to stratify patients for motor function tests and clinical trials. Our aim was to compare three methods, marker analysis, real-time quantitative polymerase chain reaction using the LightCycler instrument, and multiple ligation-dependent probe amplification (MLPA), to characterize their accuracy in quantifying SMN2 genes. We studied a group of 62 genetically confirmed SMA patients, 54 with homozygous absence of exons 7 and 8 of SMN1 and 8 with SMN2-SMN1 hybrid genes. A complete correlation using the three methods was observed in 32 patients (51.6%). In the remaining 30 patients, discordances between the three methods were found, including under or overestimation of SMN2 copies by marker analysis with respect to the quantitative methods (LightCycler and MLPA) because of lack of informativeness of markers, 3' deletions of SMN genes, and breakpoints in SMN2-SMN1 hybrid genes. The technical limitations and advantages and disadvantages of these methods are discussed. We conclude that the three methods complement each other in estimating the SMN2 copy number in most cases. However, MLPA offers additional information to characterize SMA cases with particular rearrangements such as partial deletions and hybrid genes.
authors.affiliation: Servicio de Genética, Hospital de la Santa Creu i Sant Pau, CIBERER (U705), Barcelona, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Alías
authors.forename: Sara
authors.initials: S
authors.lastname: Bernal
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Barceló
authors.forename: Eva
authors.initials: E
authors.lastname: Also-Rallo
authors.forename: Rebeca
authors.initials: R
authors.lastname: Martínez-Hernández
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Rodríguez-Alvarez
authors.forename: Concepción
authors.initials: C
authors.lastname: Hernández-Chico
authors.forename: Montserrat
authors.initials: M
authors.lastname: Baiget
authors.forename: Eduardo F
authors.initials: EF
authors.lastname: Tizzano
mesh_terms: D018628:Gene Dosage; D005819:Genetic Markers / Q000235:genetics; D006801:Humans; D007223:Infant; D022521:Ligase Chain Reaction / Q000379:methods* / Q000592:standards; D018895:Microsatellite Repeats / Q000235:genetics; D008954:Models, Biological; D060885:Multiplex Polymerase Chain Reaction / Q000379:methods* / Q000592:standards; D009134:Muscular Atrophy, Spinal / Q000175:diagnosis / Q000235:genetics*; D010375:Pedigree; D060888:Real-Time Polymerase Chain Reaction / Q000379:methods* / Q000592:standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D055540:Survival of Motor Neuron 2 Protein / Q000235:genetics
chemical_list: D005819:Genetic Markers; C526477:SMN2 protein, human; D055540:Survival of Motor Neuron 2 Protein